The Patent Finder
SP

Sun Pharmaceutical Industries, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

237 patents currently held

9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Oct 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
58
Ending by 2030
Oct 2027
Next term end
135
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Deuterium-Substituted Xanthine Derivatives and Methods of Use US 8,987,442
Cited by 60 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than Mar 2029 · Low confidence
Also notable
Methods for Photodynamic Therapy US 10,357,567
Cited by 41 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2038.
Ends Jan 2038 · High confidence
Also notable
4-Hydroxybutyric Acid Analogs US 8,461,197
Cited by 85 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Ends Aug 2030 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Nov 21, 2026
  • 1 fee due Dec 2, 2026
    The maintenance fee for Concentrated Aqueous Azalide Formulations (US 9,044,508) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
  • 11 fees due Jan 2 to 23, 2027 · next Jan 2
  • 4 fees due Feb 6 to 20, 2027 · next Feb 6
  • 6 fees due Mar 10 to 29, 2027 · next Mar 10
  • 4 fees due Apr 1 to 24, 2027 · next Apr 1
  • 4 fees due May 3 to 21, 2027 · next May 3
  • 2 fees due Jun 1 to 8, 2027 · next Jun 1
  • 7 fees due Jul 7 to 26, 2027 · next Jul 7
  • 7 fees due Aug 2 to 23, 2027 · next Aug 2
  • 6 fees due Sep 1 to 30, 2027 · next Sep 1
  • 2 fees due Oct 9 to 12, 2027 · next Oct 9
  • 3 fees due Nov 3 to 17, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

  • 5 of the patents on this record were granted since Aug 23, 2026

What they patent

The largest of its 135 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,795,231Concentrated Aqueous Azalide Formulations
In force
 · High confidence
In forceHigh confidence
US 8,080,549Endothelin Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
US 8,445,698A Process for the Preparation of an Intermediate of Tadalafil
In force
 · High confidence
In forceHigh confidence
US 8,664,265Stable Dosage Forms of Spiro and Dispiro 1,2,4-Trioxolane Antimalarials
In force
 · Medium confidence
In forceMedium confidence
US 8,318,754Novel Pyrimidinecarboxamide Derivatives
In force
 · Low confidence
In forceLow confidence
US 7,943,620Anti-Anginal Compounds
In force
 · High confidence
In forceHigh confidence
US 8,227,464Substituted Oxazolidinone Derivatives
In force
 · High confidence
In forceHigh confidence
US 7,985,750Substituted Oxazolidinone Derivatives
In force
 · High confidence
In forceHigh confidence
US 9,133,137Derivatives of Gefitinib
In force
 · High confidence
In forceHigh confidence
US 8,263,601Deuterium Substituted Xanthine Derivatives
In force
 · Low confidence
In forceLow confidence
10 of 237 patents shown.
Pro members see all 237.
Pro members: see all 237 patents
Also on record, not counted in the 237: 9 patents in force now held by others · 113 patents ended · 62 applications pending · 112 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited